drugset / Trial / NCT00159822
Voriconazole For Chronic Bronchopulmonary Aspergillosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary
Timeline
- Start
- 2005-07
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voriconazole | Small molecule | 4 mg/kg | Oral |
| Subject | Voriconazole | Small molecule | 200 mg | Oral |